Le Lézard
Classified in: Health

Use of HIV Preexposure Prophylaxis May Increase Use of Primary Care, Study Shows


BOSTON, July 19, 2018 /PRNewswire-PRWeb/ -- Users of HIV preexposure prophylaxis (PrEP), a daily pill to prevent HIV infection, are more likely to use non-HIV-related primary care services, according to a new study led by researchers from Harvard Pilgrim Health Care Institute, Harvard Medical School, The Fenway Institute, and the Centers for Disease Control and Prevention.

The new study, which was published in the American Journal of Public Health, examined a group of nearly 6000 potential PrEP candidates at Fenway Health, a Boston, Massachusetts community health clinic. The investigators found that PrEP users were more likely to receive influenza vaccination, more likely to be screened for tobacco use and depression, and more likely to receive glucose testing, which is used for diabetes screening and monitoring.

Daily oral PrEP, using a combination of the antiretroviral medications emtricitabine and tenofovir (Truvada), is highly effective in preventing HIV infection. PrEP could provide a gateway to other types of health care for people at risk of HIV infection, just as family planning clinics provide a gateway to care for many women. However, prior studies have not evaluated whether PrEP use is associated with receiving routinely recommended primary care.

"To our knowledge, this is the first study to identify an association between PrEP use and receipt of primary care," said lead author Julia L. Marcus, PhD, MPH, Assistant Professor of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute, and Adjunct Faculty at The Fenway Institute. "Although this was a cross-sectional study, which limits our ability to draw conclusions about causation, our results suggest that the benefits of PrEP may extend to behavioral health, mental health, and the prevention and treatment of other infectious and chronic diseases."

Most PrEP users in the U.S. are gay and bisexual men, a population that experiences a higher risk of mental health conditions, substance use, and smoking. For this reason, PrEP users stand to benefit from the increased opportunities for non-HIV-related screening and treatment that are provided by the PrEP care package.

"Our study suggests that PrEP users may be motivated to care for their health in other ways," said senior author Kenneth H. Mayer, MD, of The Fenway Institute and Harvard Medical School. "This increased engagement in health care may be a reason for PrEP initiation or may actually result from the experience of using PrEP."

The study authors suggest that, in addition to efforts to integrate PrEP prescribing into primary care, efforts may be warranted to ensure uptake of recommended primary care among PrEP users.

The paper, "HIV Preexposure Prophylaxis as a Gateway to Primary Care," was published July 19 in American Journal of Public Health (AJPH).

The Harvard Pilgrim Health Care Institute's Department of Population Medicine is a unique collaboration between Harvard Pilgrim Health Care and Harvard Medical School. Created in 1992, it is the only appointing medical school department in the United States based in a health plan. The Institute focuses on improving health care delivery and population health through innovative research and teaching.

Since 1971, Fenway Health has been working to make life healthier for the people in our neighborhood, the LGBT community, people living with HIV/AIDS, and the broader population. The Fenway Institute at Fenway Health is an interdisciplinary center for research, training, education, and policy development focusing on national and international health issues.

 

SOURCE Fenway Health


These press releases may also interest you

at 05:15
Every year in Quebec, more than 2,000 young people leave the care of the Director of Youth Protection (DYP) as they approach the age of majority. For youth under the care of the DYP, turning 18 means having to become independent quickly, with little...

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....



News published on and distributed by: